Literature DB >> 28209655

Mutational analysis in serial marrow samples during azacitidine treatment in patients with post-transplant relapse of acute myeloid leukemia or myelodysplastic syndromes.

Janghee Woo1,2, Nicholas P Howard2, Barry E Storer1, Min Fang1, Cecilia C Yeung1, Bart L Scott1, H Joachim Deeg3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28209655      PMCID： PMC5451346          DOI： 10.3324/haematol.2016.162909

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  9 in total

1.  Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study.

Authors:  Marcos de Lima; Sergio Giralt; Peter F Thall; Leandro de Padua Silva; Roy B Jones; Krishna Komanduri; Thomas M Braun; Hoang Q Nguyen; Richard Champlin; Guillermo Garcia-Manero
Journal:  Cancer       Date:  2010-07-29       Impact factor: 6.860

2.  Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia.

Authors:  Charles Craddock; Myriam Labopin; Marie Robin; Juergen Finke; Patrice Chevallier; Ibrahim Yakoub-Agha; Jean Henri Bourhis; Henrik Sengelov; Didier Blaise; Thomas Luft; Michael Hallek; Nicolaus Kröger; Arnon Nagler; Mohamad Mohty
Journal:  Haematologica       Date:  2016-04-14       Impact factor: 9.941

3.  Factors Determining Responses to Azacitidine in Patients with Myelodysplastic Syndromes and Acute Myeloid Leukemia with Early Post-Transplantation Relapse: A Prospective Trial.

Authors:  Janghee Woo; H Joachim Deeg; Barry Storer; Cecilia Yeung; Min Fang; Marco Mielcarek; Bart L Scott
Journal:  Biol Blood Marrow Transplant       Date:  2016-10-24       Impact factor: 5.742

4.  Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation.

Authors:  Rafael Bejar; Kristen E Stevenson; Bennett Caughey; R Coleman Lindsley; Brenton G Mar; Petar Stojanov; Gad Getz; David P Steensma; Jerome Ritz; Robert Soiffer; Joseph H Antin; Edwin Alyea; Philippe Armand; Vincent Ho; John Koreth; Donna Neuberg; Corey S Cutler; Benjamin L Ebert
Journal:  J Clin Oncol       Date:  2014-08-04       Impact factor: 44.544

5.  Outcomes among patients with recurrent high-risk hematologic malignancies after allogeneic hematopoietic cell transplantation.

Authors:  Marco Mielcarek; Barry E Storer; Mary E D Flowers; Rainer Storb; Brenda M Sandmaier; Paul J Martin
Journal:  Biol Blood Marrow Transplant       Date:  2007-08-03       Impact factor: 5.742

6.  Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia.

Authors:  Timothy J Ley; Christopher Miller; Li Ding; Benjamin J Raphael; Andrew J Mungall; A Gordon Robertson; Katherine Hoadley; Timothy J Triche; Peter W Laird; Jack D Baty; Lucinda L Fulton; Robert Fulton; Sharon E Heath; Joelle Kalicki-Veizer; Cyriac Kandoth; Jeffery M Klco; Daniel C Koboldt; Krishna-Latha Kanchi; Shashikant Kulkarni; Tamara L Lamprecht; David E Larson; Ling Lin; Charles Lu; Michael D McLellan; Joshua F McMichael; Jacqueline Payton; Heather Schmidt; David H Spencer; Michael H Tomasson; John W Wallis; Lukas D Wartman; Mark A Watson; John Welch; Michael C Wendl; Adrian Ally; Miruna Balasundaram; Inanc Birol; Yaron Butterfield; Readman Chiu; Andy Chu; Eric Chuah; Hye-Jung Chun; Richard Corbett; Noreen Dhalla; Ranabir Guin; An He; Carrie Hirst; Martin Hirst; Robert A Holt; Steven Jones; Aly Karsan; Darlene Lee; Haiyan I Li; Marco A Marra; Michael Mayo; Richard A Moore; Karen Mungall; Jeremy Parker; Erin Pleasance; Patrick Plettner; Jacquie Schein; Dominik Stoll; Lucas Swanson; Angela Tam; Nina Thiessen; Richard Varhol; Natasja Wye; Yongjun Zhao; Stacey Gabriel; Gad Getz; Carrie Sougnez; Lihua Zou; Mark D M Leiserson; Fabio Vandin; Hsin-Ta Wu; Frederick Applebaum; Stephen B Baylin; Rehan Akbani; Bradley M Broom; Ken Chen; Thomas C Motter; Khanh Nguyen; John N Weinstein; Nianziang Zhang; Martin L Ferguson; Christopher Adams; Aaron Black; Jay Bowen; Julie Gastier-Foster; Thomas Grossman; Tara Lichtenberg; Lisa Wise; Tanja Davidsen; John A Demchok; Kenna R Mills Shaw; Margi Sheth; Heidi J Sofia; Liming Yang; James R Downing; Greg Eley
Journal:  N Engl J Med       Date:  2013-05-01       Impact factor: 91.245

7.  TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients.

Authors:  Rafael Bejar; Allegra Lord; Kristen Stevenson; Michal Bar-Natan; Albert Pérez-Ladaga; Jacques Zaneveld; Hui Wang; Bennett Caughey; Petar Stojanov; Gad Getz; Guillermo Garcia-Manero; Hagop Kantarjian; Rui Chen; Richard M Stone; Donna Neuberg; David P Steensma; Benjamin L Ebert
Journal:  Blood       Date:  2014-09-15       Impact factor: 22.113

8.  Clinical and biological implications of driver mutations in myelodysplastic syndromes.

Authors:  Elli Papaemmanuil; Moritz Gerstung; Luca Malcovati; Sudhir Tauro; Gunes Gundem; Peter Van Loo; Chris J Yoon; Peter Ellis; David C Wedge; Andrea Pellagatti; Adam Shlien; Michael John Groves; Simon A Forbes; Keiran Raine; Jon Hinton; Laura J Mudie; Stuart McLaren; Claire Hardy; Calli Latimer; Matteo G Della Porta; Sarah O'Meara; Ilaria Ambaglio; Anna Galli; Adam P Butler; Gunilla Walldin; Jon W Teague; Lynn Quek; Alex Sternberg; Carlo Gambacorti-Passerini; Nicholas C P Cross; Anthony R Green; Jacqueline Boultwood; Paresh Vyas; Eva Hellstrom-Lindberg; David Bowen; Mario Cazzola; Michael R Stratton; Peter J Campbell
Journal:  Blood       Date:  2013-09-12       Impact factor: 22.113

9.  Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia.

Authors:  Terrence N Wong; Giridharan Ramsingh; Andrew L Young; Christopher A Miller; Waseem Touma; John S Welch; Tamara L Lamprecht; Dong Shen; Jasreet Hundal; Robert S Fulton; Sharon Heath; Jack D Baty; Jeffery M Klco; Li Ding; Elaine R Mardis; Peter Westervelt; John F DiPersio; Matthew J Walter; Timothy A Graubert; Timothy J Ley; Todd Druley; Daniel C Link; Richard K Wilson
Journal:  Nature       Date:  2014-12-08       Impact factor: 49.962
  9 in total
  8 in total

Review 1.  Hypomethylating agents for treatment and prevention of relapse after allogeneic blood stem cell transplantation.

Authors:  Thomas Schroeder; Christina Rautenberg; Rainer Haas; Ulrich Germing; Guido Kobbe
Journal:  Int J Hematol       Date:  2017-11-15       Impact factor: 2.490

2.  Subclones dominate at MDS progression following allogeneic hematopoietic cell transplant.

Authors:  Meagan A Jacoby; Eric J Duncavage; Gue Su Chang; Christopher A Miller; Jin Shao; Kevin Elliott; Joshua Robinson; Robert S Fulton; Catrina C Fronick; Michelle O'Laughlin; Sharon E Heath; Iskra Pusic; John S Welch; Daniel C Link; John F DiPersio; Peter Westervelt; Timothy J Ley; Timothy A Graubert; Matthew J Walter
Journal:  JCI Insight       Date:  2018-03-08

Review 3.  Genetics of progression from MDS to secondary leukemia.

Authors:  Andrew J Menssen; Matthew J Walter
Journal:  Blood       Date:  2020-07-02       Impact factor: 22.113

4.  A prognostic score including mutation profile and clinical features for patients with CMML undergoing stem cell transplantation.

Authors:  Nico Gagelmann; Anita Badbaran; Dietrich W Beelen; Rachel B Salit; Friedrich Stölzel; Christina Rautenberg; Heiko Becker; Aleksandar Radujkovic; Victoria Panagiota; Rashit Bogdanov; Maximilian Christopeit; Yong Park; Olivier Nibourel; Thomas Luft; Michael Koldehoff; Maarten Corsten; Michael Heuser; Jürgen Finke; Guido Kobbe; Uwe Platzbecker; Marie Robin; Bart L Scott; Nicolaus Kröger
Journal:  Blood Adv       Date:  2021-03-23

5.  Mutation Clearance after Transplantation for Myelodysplastic Syndrome.

Authors:  Eric J Duncavage; Meagan A Jacoby; Gue Su Chang; Christopher A Miller; Natasha Edwin; Jin Shao; Kevin Elliott; Joshua Robinson; Haley Abel; Robert S Fulton; Catrina C Fronick; Michelle O'Laughlin; Sharon E Heath; Kimberly Brendel; Raya Saba; Lukas D Wartman; Matthew J Christopher; Iskra Pusic; John S Welch; Geoffrey L Uy; Daniel C Link; John F DiPersio; Peter Westervelt; Timothy J Ley; Kathryn Trinkaus; Timothy A Graubert; Matthew J Walter
Journal:  N Engl J Med       Date:  2018-09-13       Impact factor: 91.245

6.  Impending relapse of myelodysplastic syndrome after allogeneic transplant is difficult to diagnose and requires a multi-modal approach.

Authors:  Elizabeth L Courville; Megan Griffith; Celalettin Ustun; Sophia Yohe; Erica Warlick
Journal:  BMC Clin Pathol       Date:  2017-12-28

7.  Impact of clinical, cytogenetic, and molecular profiles on long-term survival after transplantation in patients with chronic myelomonocytic leukemia.

Authors:  Janghee Woo; Dae Ro Choi; Barry E Storer; Cecilia Yeung; Anna B Halpern; Rachel B Salit; Mohamed L Sorror; David W Woolston; Tim Monahan; Bart L Scott; H Joachim Deeg
Journal:  Haematologica       Date:  2019-07-09       Impact factor: 9.941

8.  Heterogeneous genetic and non-genetic mechanisms contribute to response and resistance to azacitidine monotherapy.

Authors:  Vasiliki Symeonidou; Marlen Metzner; Batchimeg Usukhbayar; Aimee E Jackson; Sonia Fox; Charles F Craddock; Paresh Vyas
Journal:  EJHaem       Date:  2022-07-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.